HLB Life Science Signs Memorandum of Understanding for Research and Development with AI Drug Company Oncocross

[Asia Economy Reporter Yoo Hyun-seok] HL Biopharma and AI drug development company Oncocross are collaborating on anticancer drug research.

HL Biopharma announced on the 12th that it has signed a memorandum of understanding (MOU) for joint research and development of new drug pipelines, including exploring optimal indications for new drug candidates and existing drugs using the AI platform developed by Oncocross.

Through this MOU, the two companies will form a business alliance for joint research and development and cooperate mutually. HL Biopharma, which possesses multiple innovative anticancer drug substances such as Rivoceranib and Pyrotinib, is continuously striving to expand its pipeline through the discovery of new anticancer agents. The company expects that this collaboration, as part of these efforts, will significantly reduce the cost and time required to discover candidate substances for treating intractable cancers by actively utilizing Oncocross's AI technology platform.

Oncocross is a unique drug development company possessing AI engine platform technology. This platform technology is an innovative system where the AI engine 'RAPTOR AI' analyzes gene expression patterns of cancer cells to generate big data, which is then applied to new drug candidates and existing drugs to identify effective indications.

Han Yong-hae, Head of Bio at HL Biopharma, said, "Following the recent launch of HL Biopharma's new drug research institute, we plan to strengthen our anticancer drug pipeline through close cooperation with Oncocross, which possesses AI platform technology. We will combine the technical strengths of both companies to focus on early discovery and rapid development of anticancer substances."

Kim I-rang, CEO of Oncocross, stated, "We will actively cooperate to make this an opportunity to secure and add to the anticancer drug pipeline by combining Oncocross's AI technology with HL Biopharma's existing anticancer research and development."

Last month, HL Biopharma established a new drug research institute in Dongtan, Gyeonggi Province. Through active open innovation with domestic and international universities, national research institutes, ventures, and mid-sized companies, it is conducting research to secure early-stage anticancer drugs as well as mechanism studies of anticancer drugs in clinical stages and exploration of new indications.

This content was produced with the assistance of AI translation services.